Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial ...
IFLScience needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results